NCT07653386Completed
Clinical Trial of an Ointment in Patients With Mild and Moderate Atopic Dermatitis
Clinical Trial to Evaluate the Safety and Efficacy of Theraphytoabel Theraphyto Intensive-Cure Ointment Product in Mild and Moderate Atopic Dermatitis Patients at Vinmec International Hospital Times City
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
Atopic dermatitis (AD) is a chronic skin disorder, which negatively impacts up to 20% children and 3% adults in the world. The main AD treatments aim to regress clinical manifestations, improve and restore skin lesions. Daily moisturizing has also been shown to have the ability to protect the skin, increase skin elasticity and reduce the severity of AD. In the past few decades, Korea has been a well-known country with cosmetic companies and products derived from nature. Carboexpert is also one of them. Since its inception, the company has focused on researching and developing herbal extracts in skin care cosmetic products, typically the product Theraphytoabel Theraphyto Intensive-Cure Ointment. The product uses a high concentration of extract from Syzygium formosum (Wall) masam leaves originating from Vietnam. This is a medicinal herb that has been used in Vietnam for hundreds of years. Folk remedies in Vietnam use hot water leaf extract of this plant to treat urticaria and rashes. Previous studies have shown that leaf extract has also been shown to be very effective against gram-positive bacteria. The study in 2018 also demonstrated that the ethanol extract of S. formosum leaves was effective in reducing food allergy on mouse model. Based on the above evidences, this study will evaluate and compare the effectiveness and safety between Theraphytoabel Theraphyto Intensive-Cure Ointment product and commercial moisturizers which using in Vinmec on moderate and mild AD patients at Vinmec International Hospital Times City, Hanoi.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 4 Jun 2026
- Start date
- 23 Feb 2025
- Primary completion date
- 31 Oct 2025
- Lead sponsor
- VinUniversity
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07653386
What you commit to
- Study type: Interventional
- Participants enrolled: 90
- From 23 Feb 2025 to the primary completion date, 31 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Non-adherence to therapy
- Severe AD within 1 month prior to enrollment
- Any concomitant disease that in the investigators' judgment, could interdere with treatment
Other illness
- Presence of other active skin diseases
Other
- Current systemic treatment or use of immunosuppressive or immunomodulatory agents
Who the study is looking for
- Age between 1 and 30 years of age
- Definitive diagnosis of AD according to the Hanifin and Rajka criteria SCORAD scores: \< 25: mild AD, 26- 50: moderate AD
- Total IgE and eosinophil measurements could be performed to access disease severity
Age in the registry: 1 year to 30 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vinmec - VinUni Institute of Immunology, VinUniversity Coordinator of this site? Confirm its status | Hanoi | Vietnam | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.